Thank you for your patience while your manuscript was peer-reviewed at EMBO reports. I am very sorry for the delay in getting back to you, which is due to the difficulty to find referees over the Christmas break. We have finally received the full set of referee reports on your manuscript that is copied below.
As you will see, the referees acknowledge that the findings are potentially interesting and novel. However, all three referees point out that Atg5 expression does not precisely and not only correlate with gliogenesis. Referees 2 and 3 further remark that the mechanism by which Atg5 affects astrocyte differentiation (involving SOCS2) needs to be better worked out and strengthened by additional experimental evidence. Given that both referees mention this concern, and referee 3 thinks this is an important component of the paper, this is a crucial point that must be addressed. Referee 3 adds that alternative cell fates after changes in Atg5 expression need to be examined, and that it needs to be distinguished whether Atg5 regulates astrocyte numbers or timing of differentiation. Both referees 1 and 3 further raise concerns about the rapamycin experiment, and referee 3 remarks that not gliogenesis but astrocyte differentiation is investigated. The title and manuscript text need to make this clear. Referee 1 also has concerns with the interpretation of the data, asks for additional controls, and points out that the findings should be better related to published work. The suggestion by this referee to also knockdown other components of the autophagy machinery is welcome, but such experiments are not strictly required for publication of the manuscript here. Regarding the critical comment on the unaffected brain architecture after Atg5 depletion, please see the cross comments from referee 3, who does not fully agree with this concern.
Given these constructive comments, we would like to invite you to revise your manuscript with the understanding that the referee concerns (as mentioned above and in their reports) must be fully addressed and their suggestions taken on board. I realize that addressing all points requires major revisions, and please let me know if you prefer to rather publish the manuscript elsewhere, or if you need more time than the suggested 3 months for these revisions.
Acceptance of the manuscript will depend on a positive outcome of a second round of review. It is EMBO reports policy to allow a single round of revision only and acceptance or rejection of the manuscript will therefore depend on the completeness of your responses included in the next, final version of the manuscript.
Revised manuscripts should be submitted within three months of a request for revision; they might otherwise be treated as new submissions. Also, the revised manuscript may not exceed 30,000 characters (including spaces, references and figure legends) and 5 main plus 5 supplementary figures, which should directly relate to their corresponding main figure. The current text largely exceeds our limits, and therefore needs to be substantially shortened. Shortening may be made easier by combining the results and discussion sections, which may also eliminate some redundancy that is inevitable when discussing the same experiments twice. Commonly used materials and methods can further be moved to the supplementary information, but please note that materials and methods essential for the understanding of the experiments described in the main text must remain in the main manuscript file.
Importantly, regarding data quantification, please specify the number "n" for how many experiments were performed, the bars and error bars (e.g. SEM, SD) and the tests used to calculate p-values in all the relevant figure legends. This information must be provided in the figure legends.
I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have any questions regarding the revision.
REFEREE REPORTS:
Referee #1:
As the title of this study by Jiao and colleagues suggests the authors propose that Atg5 may play a critical role in gliogenesis in the developing cortex. The study is performed primarily using RNA interference in the form of anti ATG5 shRNA, and then followed by immunofluorescence. The authors also attempt to link a mechanism to their observations, suggesting that it is due to dysregulation of the JAK-STAT pathway. The predominant focus on the field of macroautophagy in the CNS has been on neurons, and thus an examination of glia is both novel and interesting. Unfortunately, there are some fundamental issues with the work that significantly diminishes its appeal. A primary issue, especially for a journal such as EMBO, is that the work fails to contextualize its findings with respect to the previously performed work of many labs that have genetically eliminated both constitutively and conditionally components of the macroautophagic pathway. Gliogenesis is also important regulators of neuronal architecture, and gross architectural changes have not been reported in any of the models. Examination of the original work by the Mizushima group shows that the Atg5 KO brain does not show gross structural abnormalities. No defects have been reported also with the Atg7 or Atg14 KO. With respect to the work presented by Jiao and colleagues, the formation of key glial populations (that are GFAP positive) would influence major events such as the formation of major axonal tracts such as the corpus callosum. Moreover, the work presented examines only Atg5. A lentivirus mediated approach permits the authors to examine multiple components involved in autophagosome building. By limiting their approach, it strongly limits the interpretation of the findings. Another issue is, unfortunately, some of the data itself. The LC3 blots cannot be interpreted. There is a single band shown. What is this? Why only a single band? This is even more puzzling as it is at times used as an indicator of macroautophagy activation (such as in Figure 4 ). At other times both LC3I and LC3II are presented, but what is confusing is that LC3II is shown to form even in the absence of Atg5 (figure 1). Although early figures suggest that the atg5 knockdown in principle works, each infection event will yield a different result. How do we know which cells are infected? What percentage of neural precursors versus glial precursors is affected? How efficient is transduction at each event?
In Figure 4 , the authors suggest that rapamycin rescues the autophagy defect due to Atg5 depletion. It's puzzling that LC3 conversion can be rescued by rapamycin. What does this mean? While the LC3 western blot accompanying this data is a single band, it is unclear at all what the rapamycin is rescuing. Is it protein synthesis? Finally, the opening sentence of the results, "we observed that Atg5 expression dramatically increased during the period of E12-E15, the highest level occurred at E15 and gradually decreased after E19." The data presented does not necessarily support this, or at least it is quite unclear (quantification might help). This time period also coincides with rapid change in neurogenesis, neural migration-it is unclear why this data alone is presented as correlation to gliogenesis. The interrelationship between the development of the two major neural cell types can be profound.
Referee #2:
The manuscript of Wang et al. suggests that the autophagy-related Atg5 protein is involved in astrogliogenesis. The mechanism proposed is dependent on the JAK/STAT pathway. More precisely, the authors suggest that Atg5 is important in promoting SOCS2 degradation via autophagy.
In the proposed manuscript the authors show by means of many approaches, both in vivo and in vitro, that gliogenesis is markedly affected when Atg5 expression is altered. Indeed, Atg5 reduction or increase of expression seems to finely correlate with the expression of gliogenesis markers in NPCs and in cortex tissues
The observations that specifically link Atg5 expression to astrocytes production and maturation are well supported by many different experiments and approaches. Nonetheless, the authors should comment and discuss on the fact that physiological Atg5 protein expression does not precisely temporally accompany the neurogenic to gliogenic switch (at least the GFAP increment in tissues). Instead, the peak of Atg5 expression appears at E15 (same for LC3) but GFAP starts to be expressed later on during the embryonic developmental stages (Figure 1 ).
The preliminary explanation of the mechanism described in Figure 5 needs some strengthening. Authors discuss how SOCS2 could be degraded by autophagosome recruitment but there are no solid data showing this, apart from the LC3 binding (IP in Figure 5) I think that the manuscript, once strengthened in its weak points, could be considered for publication on EMBO Reports.
Specific Remarks
Authors should include statistics and sample size to all quantification experiments. Panels in FigS2 are mislabeled.
Referee #3:
In this interesting manuscript the authors demonstrate a role of Atg5 and its associated biology in the regulation of JAK/STAT signaling during astrocyte differentiation. Using in utero electroporation and in vitro approaches they demonstrate that Atg5 is both necessary and sufficient for astrocyte differentiation in the cortex. Mechanistically, the authors use the biology surrounding Atg5 to link regulation of JAK/STAT astrocyte differentiation pathways to autophagy, by examining how Atg5/LC3 regulate SOCS, a negative regulator of JAK/STAT signaling. To this end the authors use a series of in vitro and in vivo epistasis tests and biochemistry to demonstrate pathway interactions during astrocyte differentiation.
In general the in vitro and in vivo gene manipulations are well done and convincing, and suggest a very interesting and novel regulatory mechanism by which astrocyte differentiation is regulated. However, the mechanistic studies linking Atg5/LC3/SOCS (Fig. 5E , F, H) are very poorly performed and not at all convincing. This latter half of the paper is critical, as it provides a detailed explanation for the effects of Atg5 on astrocyte differentiation, which is a necessary component of this paper.
Comments:
In Figure 1 , the Atg5 immunostaining is not restricted to the VZ or the IZ; it is also expressed in neurons. This needs to be clarified.
Also the timing of the Western blots and IHC does not correlate with the commencement of gliogenesis in the cortex. Astrocytes do not begin to be generated in the cortex until after E16.5. Hence the timing of this apparent induction does not correlate at all with the initiation of gliogenesis. This is consistent with Atg5 being expressed in cortical neurons. Hence, Atg5 expression is not as specific as the authors suggest, which is very misleading.
In Figure 2 , CD44 is not really a great marker for astrocyte precursors. Much of the staining they show looks like endothelial cells. They should try other, more accepted markers, including, GLAST, FGFR3, Aldh1l1-also see Molofsky, et al. 2012 for a list.
For both GOF and LOF of Atg5 via IUE, the authors need to address alternative cell fates. If LOF of Atg5 results in decreased astrocyte generation, does it result in increased neurogenesis? More stem cells? This issue needs to be address in order to fully understand how Atg5 is influencing cell fates.
For the GOF studies, is increased astrocyte generation the result of more astrocytes being generated OR an accelerated/precocious differentiation? This can be resolved by analyzing multiple timepoints and can resolve whether Atg5 is instructive or permissive for astrocyte formation.
The rescue experiment in Fig. S5 should be included in the main body of figure 3. This is a critical control In Figure 4 , the rapamycin experiment is not at all convincing. Rapamycin can influence cell fates through other mechanisms. I would be very careful about what assertions I made based on rapamycin studies.
In Figure 5 , (as also mentioned above) panels E, F, and H are not at all convincing and cast serious doubt on the mechanism proposed. These experiments need to be repeated and more thoroughly examined, as I seriously doubt whether (for example) LC3 interacts with SOCS (5H) under normal circumstances.
Other comments.
In the introduction the authors make a point about JAK-STAT regulating the gliogenic switch. This is not accurate, as JAK/STAT has been linked to astrocyte differentiation, not glial specification. Also, the paper address astrocyte differentiation, not the gliogenic switch. This part of the introduction needs to be clarified.
At the bottom of page 13 the author say that reference 36 demonstrates that "Atg5 overexpression activated STAT3 phosphorylation and promoted GFAP expression". The reference in question does not at all examine Atg5, so I'm not sure whether this is typo or poorly sentence structure.
Cross-comments from referee 3 on the report by referee 1:
I had a few of the same concerns regarding previous studies on the Atg5-KO. However, the previous studies did not adequately examine developmental gliogenesis, therefore its hard to compare those studies with the current studies. The fact that there are no gross abnormalities in brain architecture in the Atg5-KO does not necessarily mean that it does not effect gliogenesis. For example, it is possible that Atg5 controls the timing of astrocyte differentiation and its manipulation impacts WHEN astrocytes are generated, not their gross production. Also, there are multiple, redundant programs that regulate astrocyte differentiation and its possible that compensation by these factors or other Atg-family members results in a milder phenotype. Also, there could be some confusion regarding function and development: just because the normal development of a cell lineage is impaired, does not necessarily mean that the function of that cell will be impaired. In this case, if less astrocytes are produced, those astrocytes that remain may have normal functions. In this case, you may not see any gross defects in brain architecture and this does not mean the process is not important for development.
Generally, it might be a good idea to look at astrocyte development in the Atg5-KO; though phenotypes may be subtle and require a very careful E12 -P14 developmental timecourse analysis. Not this sure this practical for this group. Resolving the issue of timing versus gross cellular production using in vitro and IUE may be another way to assuage these concerns. Thank you all for your time and effort in carefully reviewing our manuscript. We are happy that all the reviewers are positive to our work, and give a lot of constructive comments, which help us strengthen our story. In this revision, we are addressing those questions.
Reviewer #1 :
Related questions:
1.
As the title of this study by Jiao and colleagues suggests the authors propose that Atg5 may play a critical role in gliogenesis in the developing cortex. The study is performed primarily using RNA interference in the form of anti ATG5 shRNA, and then followed by immunofluorescence. The authors also attempt to link a mechanism to their observations, suggesting that it is due to dysregulation of the JAK-STAT pathway.
The predominant focus on the field of macroautophagy in the CNS has been on neurons, and thus an examination of glia is both novel and interesting. Unfortunately, there are some fundamental issues with the work that significantly diminishes its appeal.
A primary issue, especially for a journal such as EMBO, is that the work fails to contextualize its findings with respect to the previously performed work of many labs that have genetically eliminated both constitutively and conditionally components of the macroautophagic pathway. Gliogenesis is also important regulators of neuronal architecture, and gross architectural changes have not been reported in any of the models. Examination of the original work by the Mizushima group shows that the Atg5 KO brain does not show gross structural abnormalities. No defects have been reported also with the Atg7 or Atg14 KO. With respect to the work presented by Jiao and colleagues, the formation of key glial populations (that are GFAP positive) would influence major events such as the formation of major axonal tracts such as the corpus callosum. Moreover, the work presented examines only Atg5. A lentivirus mediated approach permits the authors to examine multiple components involved inautophagosome building. By limiting their approach, it strongly limits the interpretation of the findings.
Thanks for your critical comments and suggestions which are all based on a scientific logic. As we all know, autophagy is a basic physiologic progress and plays a key role in normal turnover of cytoplasmic contents. The work of Mizushima group is excellent. They found that loss of autophagy in the central nervous system causes neurodegeneration in Atg5 knockout mice (Hara, et al, Nature, 2006) . However, they did not check the detailed brain development such as brain size, neurogenesis, and gliogenesis. From Fig1b in their paper, the body size and brain size is clearly smaller in Atg5 knockout mice than that in wildtype mice. It is also reported that neurogenesis is affected by the deletion of Atg5 (Vázquez, et al. Autophagy. 2012) . Also, it is reported that another autophagy molecule of Ambra1 regulates autophagy and development of the nervous system (Fimia, et al. Nature. 2007 ). Therefore, basal autophagy is important for brain development. However, it is largely unknown whether basal autophagy is involved in the regulation of astrocyte differentiation in the developing brain. Here, we show that knockdown Atg5 causes astrocyte differentiation defect in brain development.
As the Referee 3 said that "The fact that there are no gross abnormalities in brain architecture in the Atg5-KO does not necessarily mean that it does not affect gliogenesis. For example, it is possible that Atg5 controls the timing of astrocyte differentiation and its manipulation impacts when astrocytes are generated, not their gross production. Also, there are multiple, redundant programs that regulate astrocyte differentiation and its possible that compensation by these factors or other Atg-family members results in a milder phenotype. Also, there could be some confusion regarding function and development: just because the normal development of a cell lineage is impaired, does not necessarily mean that the function of that cell will be impaired. In this case, if less astrocytes are produced, those astrocytes that remain may have normal functions. In this case, you may not see any gross defects in brain architecture and this does not mean the process is not important for development."
In the first submission, we only used Atg5 shRNA knockdown strategy to examine astrocyte differentiation. According to reviewer comment, we obtained Atg5
(flox/flox) mice in Feb 2014 from
Riken animal center to further confirm the results. In this revision, we electroporated Cre vector to Atg5 (flox/flox) mice brain to knockout Atg5 at E16 and P0 respectively and did the same manipulation study as Atg5 shRNA experiments. The results were similar as those of Atg5 knockdown and shown in Figure 4 . We also checked the phenotype of Atg7 on astrocyte differentiation and found that knockdown Atg7 affected astrocyte differentiation as well. The data indicate basal autophagy is important for astrocyte differentiation.
2. Another issue is, unfortunately, some of the data itself. The LC3 blots cannot be interpreted. There is a single band shown. What is this? Why only a single band? This is even more puzzling as it is at times used as an indicator of macroautophagy activation (such as in Figure  4 ). Under normal condition, the level of autophagy is low in the cerebral cortex and it is not easy to obtain the clear LC3II band. However, we try to load more proteins to obtain LC3II band and all LC3 western blot figures (Fig 1A, supplementary Fig S4C, Fig S4E) have been replaced in this revision.
3. What is confusing is that LC3II is shown to form even in the absence of Atg5 (figure 1). Although early figures suggest that the atg5 knockdown in principle works, each infection event will yield a different result. How do we know which cells are infected? What percentage of neural precursors versus glial precursors is affected? How efficient is transduction at each event?
It is understandable that LC3II is formed even in the absence of Atg5 because other autophagy members are still existed. Also, the Atg5 shRNA can not completely delete Atg5, so there is a little LC3II. Even in Atg5 KO mice, there is still some LC3II. (Hara, et al, Nature, 2006) . We each time deliver the same amount of Atg5 shRNA into the ventricle of embryonic brain mice, so the knockdown efficiency should be almost the same. In our work, the cells infected by Atg5 shRNA will show GFP positive. Atg5 shRNA was delivered into brain ventricular zone (VZ) at E16 or P0 and the majority of electroporated cells around VZ are glial precursor cell at that age. The transduction efficiency is high and repeatable. A lot of labs use the same embryo electroporation technique to study brain development (Mao, et al. Cell. 2009; Li, et al. Neuron. 2012 ).
4. In Figure 4 , the authors suggest that rapamycin rescues the autophagy defect due to Atg5 depletion. It's puzzling that LC3 conversion can be rescued by rapamycin. What does this mean? While the LC3 western blot accompanying this data is a single band, it is unclear at all what the rapamycin is rescuing. Is it protein synthesis?
Due to space limit and the complicated story caused by chemical compounds, the chemical compounds related data were removed.
5. Finally, the opening sentence of the results, "we observed that Atg5 expression dramatically increased during the period of E12-E15, the highest level occurred at E15 and gradually decreased after E19." The data presented does not necessarily support this, or at least it is quite unclear (quantification might help). This time period also coincides with rapid change in neurogenesis, neural migration-it is unclear why this data alone is presented as correlation to gliogenesis. The interrelationship between the development of the two major neural cell types can be profound.
As suggested, we provide the quantification result in Figure S1 . In this work, we study astrocyte differentiation by choosing late age embryo (E16-P0 and P0-P8 , Fig 4) , during which neurogenesis and neural migration are almost over. To investigate the function of autophagy on neurogenesis, we need do In Utero Electroporation at E12.5. And we also have some data about this process, but we think that could be a new subject in our future work. In this paper, we just focus on studying astrocyte differentiation and uncover the molecular mechanism underlying this process.
1. The manuscript of Wang et al. suggests that the autophagy-related Atg5 protein is involved in astrogliogenesis. The mechanism proposed is dependent on the JAK/STAT pathway. More precisely, the authors suggest that Atg5 is important in promoting SOCS2 degradation via autophagy.
In the proposed manuscript the authors show by means of many approaches, both in vivo and in vitro, that gliogenesis is markedly affected when Atg5 expression is altered. Indeed, Atg5 reduction or increase of expression seems to finely correlate with the expression of gliogenesis markers in NPCs and in cortex tissues.
Your suggestion is right. We modified the statement as "The results showed that Atg5 expressed highly but not restricted in the ventricular zone (VZ) / subventricular zone (SVZ)". From western blot, GFAP was detected from E15 and Atg5 has high expression around period. We agree that Atg5 is not specific and has other roles for brain development. We modified the statement as "These data suggest that Atg5 might be involved in broad brain development including astrocyte differentiation."
2. The preliminary explanation of the mechanism described in Figure 5 needs some strengthening. Authors discuss how SOCS2 could be degraded by autophagosome recruitment but there are no solid data showing this, apart from the LC3 binding (IP in Figure 5 )
To verify the regulation of Atg5 on SOCS2 bridged by autophagy, the interaction between LC3 and SOCS2 were detected by IP experiments (Fig 5E and F) . Either in control normal or Flag-LC3 overexpressed circumstance, the interaction between LC3 and SOCS2 was observed. Furthermore, accumulated SOCS2 protein pulled down by LC3 was increased when cells were treated with lysosomal inhibitors (E64d and PepstatinA), which interferes with autolysosomal formation. In addition, the co-localization of LC3 and SOCS2 was observed in cells cotransfected with Flagtagged LC3 and HA-tagged SOCS2 (Supplementary Fig S5H) . These data suggest that the regulation of Atg5 on SOCS2 is carried out by the interaction between LC3 and SOCS2 and the role of Atg 5 in astrocyte differentiation is mediated by autophagy.
3. I think that the manuscript, once strengthened in its weak points, could be considered for publication on EMBO Reports.
Thanks for the support. Referee #3:
1. In this interesting manuscript the authors demonstrate a role of Atg5 and its associated biology in the regulation of JAK/STAT signaling during astrocyte differentiation. Using in utero electroporation and in vitro approaches they demonstrate that Atg5 is both necessary and sufficient for astrocyte differentiation in the cortex. Mechanistically, the authors use the biology surrounding Atg5 to link regulation of JAK/STAT astrocyte differentiation pathways to autophagy, by examining how Atg5/LC3 regulate SOCS, a negative regulator of JAK/STAT signaling. To this end the authors use a series of in vitro and in vivo epistasis tests and biochemistry to demonstrate pathway interactions during astrocyte differentiation.
Thanks for the great comments.
2. In Figure 1 , the Atg5 immunostaining is not restricted to the VZ or the IZ; it is also expressed in neurons. This needs to be clarified. Also the timing of the Western blots and IHC does not correlate with the commencement of gliogenesis in the cortex. Astrocytes do not begin to be generated in the cortex until after E16.5. Hence the timing of this apparent induction does not correlate at all with the initiation of gliogenesis. This is consistent with Atg5 being expressed in cortical neurons. Hence, Atg5 expression is not as specific as the authors suggest, which is very misleading.
Thanks for your critical comments and suggestions. We modified the statement as "The results showed that Atg5 expressed highly but not restricted in the ventricular zone (VZ) / subventricular zone (SVZ)". From western blot, GFAP was detected from E15 and Atg5 has high expression around period. We agree that Atg5 is not specific for astrocyte differentiation and has other roles for brain development. We modified the statement as "These data suggest that Atg5 might be involved in broad brain development including astrocyte differentiation." After electroporation at E16-P2, we did the immunostaining of Tuj1 as a marker for neuron and did not find difference. The results are preliminary and shown in following figures. However, we can not exclude that early neurogenesis is not affected since early neurogenesis occurs from E10 and is almost finished at E16. The embryo electroporated age at E16 for gliogenesis study is not good for neurogenesis study. Due to space and neurogenesis is another topic, we need to focus on studying astrocyte differentiation in this manuscript.
5. For the GOF studies, is increased astrocyte generation the result of more astrocytes being generated OR an accelerated/precocious differentiation? This can be resolved by analyzing multiple timepoints and can resolve whether Atg5 is instructive or permissive for astrocyte formation.
In Atg5 overexpression experiments, we choose different age of E14, E16 or P0 for electroporation, a high proportion of GFAP+GFP+ cells was all observed due to GOF of Atg5. Atg5 and related autophagy might be instructive for the process of astrocyte differentiation. It is possible that basal autophagy accelerates transformation and regulates the differentiation of astrocytes.
6. The rescue experiment in Fig. S5 should be included in the main body of figure 3. This is a critical control
Accoring to your suggestion, the main rescue experiments (Fig. S5C ) were moved to Figure 3. 7. In Figure 4 , the rapamycin experiment is not at all convincing. Rapamycin can influence cell fates through other mechanisms. I would be very careful about what assertions I made based on rapamycin studies.
Your consideration is reasonable. Rapamycin can influence cell fates through other mechanisms. After thoroughly consideration, the chemical molecule experiments were deleted in the revision.
8. In Figure 5 , (as also mentioned above) panels E, F, and H are not at all convincing and cast serious doubt on the mechanism proposed. These experiments need to be repeated and more thoroughly examined, as I seriously doubt whether (for example) LC3 interacts with SOCS (5H) under normal circumstances. The preliminary explanation of the mechanism described in Figure 5 needs some strengthening. Authors discuss how but there are no solid data showing this, apart from the LC3 binding To further verify the regulation of Atg5 on SOCS2 bridged by autophagy, the interaction between LC3 and SOCS2 were detected by IP experiments (Fig 5E and F) . Either in normal or Flag-LC3 overexpressed circumstance, the interaction between LC3 and SOCS2 was observed. Futhermore, accumulated SOCS2 protein pulled down by LC3 was increased when cells were treated with lysosomal inhibitors (E64d and PepstatinA), which interferes with autolysosomal formation. In addition, the co-location of LC3 and SOCS2 was observed in cells cotransfected with Flag-tagged LC3 and HA-tagged SOCS2 ( Supplementary Fig S5H) . These data suggest that the regulation of Atg5 on SOCS2 is carried out by the interaction between LC3 and SOCS2 and the role of Atg 5 in astrocyte differentiation is mediated by autophagy.
9. In the introduction the authors make a point about JAK-STAT regulating the gliogenic switch. This is not accurate, as JAK/STAT has been linked to astrocyte differentiation, not glial specification. Also, the paper address astrocyte differentiation, not the gliogenic switch. This part of the introduction needs to be clarified.
Thanks for your suggestions. We also think that "astrocyte differentiation" is more accurate and make some change in this revision.
2nd Editorial Decision 02 July 2014
Thank you for the submission of your revised manuscript to EMBO reports, and I apologize for the delay in getting back to you. We have now received the enclosed reports from the two referees that were asked to assess your study. As you will see, while referee 3 acknowledges that you have carefully considered most of the concerns, s/he points out that not all concerns have been addressed in a satisfactory manner and that more experimentation/data are needed to strengthen the findings. I asked referee 2 what s/he thinks about the outstanding concerns, and s/he agrees that they should be addressed (see cross-comments below). I would therefore like to give you the exceptional opportunity to perform the outstanding experiments and incorporate the suggested changes and the new data in the manuscript.
As you know, according to our policy, your manuscript must be accepted by the end of July. I am not sure how much time you will need to provide the missing data, but in case it will take you more than a few weeks, you will need to resubmit a new manuscript on the topic. The only difference will be that I will check the novelty of the findings again at the time of re-submission. At this moment, I could not find a published paper reporting similar findings. In any case, I will send your manuscript only back to referee 3 and ask her/him to get back to me within a few days, so we might be able to accept your manuscript within a month from now.
Please let me know if you have any questions or comments. I am looking forward to receiving the revised manuscript as soon as possible.
REFEREE REPORTS:
The authors significantly improved the manuscript. I am fully convinced by their rebuttal and no concerns that prevent publication.
This manuscript is much improved and it is clear that the authors carefully considered most of the points raised by the reviewers, which has resulted in a manuscript that is almost suitable for publication, provided the following issues are clarified:
1) The discussion is very thin. The results of this paper need to be put into context and many of references and explainations provided in response to reviewer #1/comment #1 serve as an adequate airing of the subject matter.
2) In figure 1A and 1C, the LC3 immunoblots are not at all convincing and severely detract from the overall data quality of the paper. Moreover, the authors state in the text that in Fig 1A LC3 increases E12-E15, then decreases at E19. The bands on the blot do not reflect this at all. In addition, they state the atg5-shRNAi reduces LC3 expression, which (again) is not the case. Also in both cases the LC3-II band (marker of autophagosomes) is uninterpretable.
3) I find it odd and intellectually lazy and thoughtless that they used comments from rev #3 to shape their response to rev #1/comment 1.
4)
Regarding comment 3. They should stain with neuronal precursor markers to show that when they EP at E16, they only hit gilal precursors.
5) Regarding reviewer 3/comment 4. The authors have not adequately addressed this topic. They show that there is no change in the number of TuJ1+ cells. What about neuronal precursors? What about neural stem cells? They authors really need to address these alternative fates, as its critical to determining which phase of astro-gilal development this mechanism is regulating (ie. early or later).
6) Regarding reviewer 3/comment 5. Again, did not address the issue at hand. The authors need to EP at E16, then harvest at various timepoints after EP to determine whether astro-glial differentiation is accelerated or if more astrocytes are generated. Precocious appearance of mature markers would suggest acceleration, while increase in the total number of astrocyte precursors would suggest more are generated. Again, distinguishing between these models is crucial for their mechanism.
Cross-comments from referee 2:
I think that some points raised by Rev #3 should be addressed and would make the manuscript more complete, carefully written and presented. In details, point 2) I agree that the figure used for LC3 could be more carefully chosen/edited and that probably a ratio between LC3II/LC3I will help quantify what it's difficult to "read" in the image. Also there is a change in Fig1 C: it does not correlate with the text and graph anymore.
In the text: the LC3II/LC3I ratio is considered an autophagy marker and not LC3 expression per se (especially if defects in autophagy are claimed).
Points 4, 5 e 6) controls suggested by the Reviewer seems reasonable and feasible in short time to rule out a role for Atg5 in neuron precursors and early vs late atro-glial development.
In sum the manuscript could really be significantly ameliorated by these few changes.
2nd Revision -authors' response 25 July 2014
Dear Reviewers, Thank you for your time and effort in reviewing our revised manuscript. And thank your for giving us detailed comments which will strengthen our story. In this revision, we try our best to address the questions in the limited time.
Reviewer #2 :
I think that some points raised by Rev #3 should be addressed and would make the manuscript more complete, carefully written and presented. In details, point 2) I agree that the figure used for LC3 could be more carefully chosen/edited and that probably a ratio between LC3II/LC3I will help quantify what it's difficult to "read" in the image. Also there is a change in Fig1 C: it does not correlate with the text and graph anymore. In the text: the LC3II/LC3I ratio is considered an autophagy marker and not LC3 expression perse (especially if defects in autophagy are claimed).
We have repeated this experiment three times and replaced the previous images, and the statistical graph was also supplied in context.
According to the suggestions of Rev #3, we did some in vivo experiments to investigate the function of Atg5 on neuron precursors, neural stem cells, and its influence on astro-gilal development.
Referee #3:
1) The discussion is very thin. The results of this paper need to be put into context and many of references and explanations provided in response to reviewer #1/comment #1 serve as an adequate airing of the subject matter.
We have modified the context and discussion.
Thanks for your critical comments. We repeated the experiments and replaced the previous images.
Thanks for great comments and we learned a lot how to write response.
4)
Regarding comment 3. They should stain with neuronal precursor markers to show that when they EP at E16, they only hit gilal precursors. address these alternative fates, as its critical to determining which phase of astro-gilal development this mechanism is regulating (ie. early or later).
6) Regarding reviewer 3/comment 5. Again, did not address the issue at hand. The authors need to EP at E16, then harvest at various timepoints after EP to determine whether astro-glial differentiation is accelerated or if more astrocytes are generated.
Precocious appearance of mature markers would suggest acceleration, while increase in the total number of astrocyte precursors would suggest more are generated. Again, distinguishing between these models is crucial for their mechanism. And the majority of Pax6 + neuronal precursor cells has been generated at early brain development before our In Utero Electroporation at E16. Scale bar: 25μm.
FIG. 3
FIG .3 is the effect of Atg5 on astrocytes precursor cell. Here, we choose the maker CD44, which was used by several groups (Barnabe-Heider et al, Neuron, 2005; Farkas et al, Neuron, 2008) . Although CD44 is not a great marker for astrocyte precursors, the result of CD44 is consistent with the results of GLAST and ALdh1L1 in our study. We can see that when we overexpress Atg5, the number of CD44 + GFP + cells was increased at E19/P2 comparing to control. It indicates that more astrocyte precursors are generated when autophay is more activated. And the tendency of this result is consistent with the result of GFAP + GFP + cell in our manuscript. Scale bar:
50μm.
FIG. 4
FIG.4 is the effect of Atg5 on mature astrocytes. Here, we choose the maker S100β.
We can see that when we overexpress Atg5, the number of S100β + cell was slightly increased and there is no significant difference at P5/P8 comparing to the control. It indicates that Atg5 could increase glia production. Scale bar: 100μm. I apologize for my delayed reply. We have received the final comments on your manuscript last week, and I am very pleased to accept it for publication in the next available issue of EMBO reports. Thank you for your contribution to our journal.
Although referee 3 did not comment on the inclusion of the "for referees only data" I think the data showing that Atg5 knockdown decreases the number of neural stem cells at the VZ/SVZ at E16 and does not affect neural precursors and mature neurons should be included as supplementary information, given that you mention these data in the last paragraph of the main manuscript text but do not show the data. You can have more than 5 supplementary figures if you want, as we have recently decided to be more flexible with the length of our manuscripts. Can you please send us a new manuscript text file and a new file with all supplementary figures and legends? Thank you very much.
I also would like to suggest a few minor changes to the title and abstract:
Autophagy Related Gene Atg5 is essential for astrocyte differentiation in the developing mouse cortex
Astrocyte differentiation is essential for late embryonic brain development, and autophagy is active during this process. However, it is unknown whether and how autophagy regulates astrocyte differentiation. Here, we show that Atg5, which is necessary for autophagosome formation, regulates astrocyte differentiation. Atg5 knockdown represses the generation of astrocytes in vitro and in vivo. Conversely, Atg5 overexpression increases the number of astrocytes substantially. We show that Atg5 activates the JAK2-STAT3 pathway by degrading the inhibitory protein SOCS2. The astrocyte differentiation defect caused by Atg5 loss can be rescued by human Atg5 overexpression, STAT3 overexpression, and SOCS2 knockdown. Together, these data demonstrate that Atg5 regulates astrocyte differentiation, with potential implications for brain disorders with autophagy deficiency.
Please let me know whether you agree with these changes.
Thank you again for your contribution to EMBO reports and congratulations on a successful publication. Please consider us again in the future for your most exciting work.
